Leif Bertilsson

List of Publications by Year in Descending Order

177 papers	12,061 citations	67 h-index	105 g-index
179 ext. papers	12,708 ext. citations	4.5 avg, IF	5.79 L-index

#	Paper	IF	Citations
177	Tribute to Folke Sj□vist, a Pioneer in Clinical Pharmacology. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 1127-1128	6.1	
176	N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians. *European Journal of Clinical Pharmacology*, **2018**, 74, 903-911	2.8	17
175	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. *BMC Pharmacology & Toxicology*, **2018**, 19, 33	2.6	11
174	Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. *European Journal of Clinical Pharmacology*, **2018**, 74, 1405-1415	2.8	6
173	Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. *Scientific Reports*, **2018**, 8, 16316	4.9	4
172	Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	6
171	Decreased Activity and Genetic Polymorphisms of CYP2C19 in Beh□t□ Disease. *Basic and Clinical Pharmacology and Toxicology*, **2017**, 121, 266-271	3.1	6
170	Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. *Journal of Clinical Pharmacology*, **2016**, 56, 1538-1549	2.9	8
169	Lower CYP2C9 activity in Turkish patients with Beh□t□ disease compared to healthy subjects: a down-regulation due to inflammation?. *European Journal of Clinical Pharmacology*, **2015**, 71, 1223-8	2.8	10
168	Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. *Pharmacogenomics*, **2015**, 16, 1047-64	2.6	16
167	Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. *OMICS A Journal of Integrative Biology*, **2015**, 19, 346-53	3.8	16
166	The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans. *Journal of Clinical Psychopharmacology*, **2015**, 35, 694-9	1.7	19
165	Genetic and Clinical Factors Affecting Plasma Clozapine Concentration. *primary care companion for CNS disorders, The*, **2015**, 17,	1.2	10
164	High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. *OMICS A Journal of Integrative Biology*, **2014**, 18, 446-53	3.8	20
163	Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. *Basic and Clinical Pharmacology and Toxicology*, **2014**, 115, 366-71	3.1	8
162	Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. *Drug Metabolism and Pharmacokinetics*, **2013**, 28, 93-7	2.2	13
161	Comparison of endogenous 4□hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. *Drug Metabolism and Disposition*, **2013**, 41, 1488-93	4	61

160	Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. *PLoS ONE*, **2013**, 8, e67946	3.7	88
159	Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. *Journal of Clinical Pharmacology*, **2012**, 52, 1527-34	2.9	14
158	Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. *European Journal of Clinical Pharmacology*, **2012**, 68, 571-7	2.8	18
157	Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. *European Journal of Clinical Pharmacology*, **2012**, 68, 1033-42	2.8	13
156	Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 55-67	2.2	143
155	4Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. *British Journal of Clinical Pharmacology*, **2011**, 71, 183-9	3.8	140
154	Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4hydroxycholesterol. *European Journal of Clinical Pharmacology*, **2011**, 67, 715-22	2.8	15
153	CYP2D6, serotonin and suicide. *Pharmacogenomics*, **2010**, 11, 903-5	2.6	10
152	Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *European Journal of Clinical Pharmacology*, **2010**, 66, 269-73	2.8	9
151	Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. *European Journal of Clinical Pharmacology*, **2010**, 66, 465-74	2.8	54
150	Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. *European Journal of Clinical Pharmacology*, **2010**, 66, 791-5	2.8	16
149	CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. *European Journal of Clinical Pharmacology*, **2010**, 66, 871-7	2.8	45
148	A comparison of haloperidol plasma levels among Japanese, Korean and Swedish psychiatric patients. *Clinical Neuropsychopharmacology and Therapeutics*, **2010**, 1, 24-31	0.2	0
147	4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. *British Journal of Clinical Pharmacology*, **2009**, 67, 38-43	3.8	93
146	Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. *Pharmacogenomics Journal*, **2009**, 9, 208-17	3.5	47
145	MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. *European Neuropsychopharmacology*, **2009**, 19, 363-70	1.2	37
144	Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. *British Journal of Clinical Pharmacology*, **2008**, 65, 708-15	3.8	37
143	Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. *British Journal of Clinical Pharmacology*, **2008**, 65, 767-74	3.8	119

142	4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. *Pharmacogenetics and Genomics*, **2008**, 18, 201-8	1.9	123
141	Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. *European Journal of Clinical Pharmacology*, **2008**, 64, 381-5	2.8	80
140	CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. *European Journal of Clinical Pharmacology*, **2008**, 64, 1163-73	2.8	60
139	Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. *European Journal of Clinical Pharmacology*, **2008**, 64, 1175-9	2.8	53
138	Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. *Fundamental and Clinical Pharmacology*, **2007**, 21, 379-86	3.1	24
137	Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. *European Journal of Clinical Pharmacology*, **2007**, 63, 537-46	2.8	193
136	Voriconazole and fluconazole increase the exposure to oral diazepam. *European Journal of Clinical Pharmacology*, **2007**, 63, 941-9	2.8	39
135	Clinical Pharmacogenetics **2007**, 179-195		2
134	CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. *Pharmacogenetics and Genomics*, **2007**, 17, 339-47	1.9	34
133	Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression. *Neuropsychopharmacology*, **2007**, 32, 2143-51	8.7	20
132	Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. *European Journal of Clinical Pharmacology*, **2006**, 62, 539-46	2.8	24
131	Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome. *Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics*, **2006**, 4, 113-119		3
130	Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 119-33	4	22
129	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. *Pharmacogenetics and Genomics*, **2006**, 16, 637-45	1.9	68
128	Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. *Pharmacogenetics and Genomics*, **2006**, 16, 565-8	1.9	38
127	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clinical Pharmacology and Therapeutics*, **2006**, 79, 103-13	6.1	523
126	Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. *Biochemical and Biophysical Research Communications*, **2005**, 338, 299-305	3.4	85
125	Pharmacogenetics of Drug Metabolism. *Drugs and the Pharmaceutical Sciences*, **2005**, 51-69		

124	Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. *Basic and Clinical Pharmacology and Toxicology*, **2004**, 95, 112-9		7
123	Dose of proton pump inhibitors and the CYP2C19 genotype. *Basic and Clinical Pharmacology and Toxicology*, **2004**, 95, 1	3.1	1
122	Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. *European Journal of Clinical Pharmacology*, **2004**, 59, 803-7	2.8	130
121	Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. *Molecular Pharmacology*, **2003**, 64, 659-69	4.3	141
120	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. *European Journal of Clinical Pharmacology*, **2003**, 59, 23-8	2.8	22
119	Metabolism and elimination of quinine in healthy volunteers. *European Journal of Clinical Pharmacology*, **2003**, 59, 423-7	2.8	42
118	Xanthine oxidase activity is influenced by environmental factors in Ethiopians. *European Journal of Clinical Pharmacology*, **2003**, 59, 533-6	2.8	25
117	The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. *Clinical Pharmacology and Therapeutics*, **2003**, 73, 517-28	6.1	107
116	Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. *British Journal of Clinical Pharmacology*, **2003**, 56, 415-21	3.8	65
115	Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. *British Journal of Clinical Pharmacology*, **2003**, 56, 679-82	3.8	50
114	Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. *British Journal of Clinical Pharmacology*, **2002**, 53, 111-22	3.8	377
113	The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. *Clinical Pharmacology and Therapeutics*, **2002**, 71, 77-88	6.1	61
112	Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). *Clinical Pharmacology and Therapeutics*, **2002**, 71, 141-52	6.1	66
111	Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. *Pharmacogenetics and Genomics*, **2002**, 12, 375-83		73
110	Clinical relevance of the CYP2D6 polymorphism for the treatment of psychiatric disorders. *International Congress Series*, **2002**, 1244, 11-20		1
109	Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. *Pharmacogenetics and Genomics*, **2001**, 11, 417-27		67
108	CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. *European Journal of Clinical Pharmacology*, **2001**, 57, 137-42	2.8	15
107	Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. *British Journal of Clinical Pharmacology*, **2001**, 52, 265-71	3.8	62

106	Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. *Clinical Pharmacology and Therapeutics*, **2001**, 70, 384-390	6.1	23
105	Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. *Clinical Pharmacology and Therapeutics*, **2001**, 70, 10-6	6.1	35
104	Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. *European Journal of Clinical Pharmacology*, **2001**, 57, 671-5	2.8	58
103	Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. *Journal of Biological Chemistry*, **2001**, 276, 38685-9	5.4	189
102	Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. *Clinical Pharmacology and Therapeutics*, **2000**, 68, 189-98	6.1	24
101	No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. *Clinical Pharmacology and Therapeutics*, **2000**, 68, 151-9	6.1	72
100	Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. *Gastroenterology*, **2000**, 119, 670-6	13.3	73
99	Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. *Therapeutic Drug Monitoring*, **2000**, 22, 409-17	3.2	108
98	Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. *Fundamental and Clinical Pharmacology*, **1999**, 13, 671-5	3.1	27
97	The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. *Clinical Pharmacology and Therapeutics*, **1999**, 66, 454-60	6.1	35
96	Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. *International Journal of Cancer*, **1999**, 81, 325-9	7.5	74
95	Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. *Pharmacogenetics and Genomics*, **1999**, 9, 657		80
94	Decreased capacity for debrisoquine metabolism among black Tanzanians. *Pharmacogenetics and Genomics*, **1999**, 9, 707-714		69
93	Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. *Journal of Clinical Psychopharmacology*, **1999**, 19, 393-400	1.7	23
92	Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. *Pharmacogenetics and Genomics*, **1999**, 9, 697-706	1.9	43
91	10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. *Clinical Pharmacology and Therapeutics*, **1998**, 63, 444-52	6.1	254
90	Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 391-401	6.1	76
89	CYP2D6 polymorphism is not crucial for the disposition of selegiline. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 402-11	6.1	20

88	Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. *Clinical Pharmacology and Therapeutics*, **1998**, 63, 529-39	6.1	111
87	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 484-91	6.1	60
86	Artemisinin induces omeprazole metabolism in human beings. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 160-7	6.1	76
85	Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 384-90	6.1	75
84	Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. *Psychiatry and Clinical Neurosciences*, **1997**, 51, 35-41	6.2	11
83	Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. *British Journal of Clinical Pharmacology*, **1997**, 44, 186-9	3.8	55
82	The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. *British Journal of Clinical Pharmacology*, **1997**, 44, 439-46	3.8	147
81	Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. *Clinical Pharmacology and Therapeutics*, **1997**, 62, 129-37	6.1	95
80	Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. *Clinical Pharmacology and Therapeutics*, **1997**, 62, 384-91	6.1	74
79	The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. *Journal of Clinical Psychopharmacology*, **1997**, 17, 467-71	1.7	35
78	Polymorphic Drug Oxidation. *CNS Drugs*, **1996**, 5, 200-223	6.7	94
77	CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. *Pharmacogenetics and Genomics*, **1996**, 6, 547-51		106
76	Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. *Pharmacogenetics and Genomics*, **1996**, 6, 441-7		92
75	S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. *Pharmacogenetics and Genomics*, **1996**, 6, 521-6		74
74	The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. *Clinical Pharmacology and Therapeutics*, **1996**, 59, 423-8	6.1	81
73	Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. *Clinical Pharmacology and Therapeutics*, **1996**, 60, 183-90	6.1	106
72	A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. *British Journal of Clinical Pharmacology*, **1996**, 42, 713-9	3.8	168
71	Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. *Clinical Pharmacokinetics*, **1995**, 28, 26-40	6.2	47

70	Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. *Clinical Pharmacokinetics*, **1995**, 29, 192-209	6.2	308
69	No Effect on Plasma Carbamazepine Concentration with Concomitant Omeprazole Treatment. *Clinical Drug Investigation*, **1995**, 9, 180-181	3.2	2
68	Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. *Pharmacogenetics and Genomics*, **1995**, 5, 159-64		88
67	Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. *Pharmacogenetics and Genomics*, **1995**, 5, 358-63		185
66	Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. *Clinical Pharmacology and Therapeutics*, **1995**, 57, 656-61	6.1	77
65	Comments to "interaction between caffeine and clozapine". *Journal of Clinical Psychopharmacology*, **1995**, 15, 376-7	1.7	9
64	Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. *Clinical Pharmacology and Therapeutics*, **1994**, 56, 176-83	6.1	51
63	The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. *Therapeutic Drug Monitoring*, **1994**, 16, 1-12	3.2	56
62	Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. *Therapeutic Drug Monitoring*, **1994**, 16, 368-74	3.2	246
61	Molecular basis of drug oxidation polymorphisms. *Nordic Journal of Psychiatry*, **1993**, 47, 27-31	2.3	
60	Genetically variable metabolism of antidepressants and neuroleptic drugs in man. *Pharmacogenetics and Genomics*, **1993**, 3, 61-70		115
59	Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?. *Clinical Pharmacology and Therapeutics*, **1993**, 53, 608-10	6.1	33
58	Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. *Basic and Clinical Pharmacology and Toxicology*, **1993**, 72, 113-5		10
57	Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. *Basic and Clinical Pharmacology and Toxicology*, **1993**, 73, 46-8		4
56	A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. *Pharmacogenetics and Genomics*, **1992**, 2, 241-3		30
55	Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. *Pharmacogenetics and Genomics*, **1992**, 2, 25-31		156
54	Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. *Clinical Pharmacology and Therapeutics*, **1992**, 51, 388-97	6.1	351
53	Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. *Therapeutic Drug Monitoring*, **1992**, 14, 261-4	3.2	94

52	Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. *Therapeutic Drug Monitoring*, **1992**, 14, 92-7	3.2	162
51	Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. *Therapeutic Drug Monitoring*, **1991**, 13, 189-94	3.2	35
50	Studies on active transport of (E)-10-hydroxynortriptyline in the kidney and brain of rats: effects of propranolol and quinidine. *Basic and Clinical Pharmacology and Toxicology*, **1991**, 68, 380-3		2
49	Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. *Basic and Clinical Pharmacology and Toxicology*, **1991**, 68, 100-3		12
48	Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics. *Psychopharmacology*, **1991**, 103, 287-90	4.7	19
47	Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. *Therapeutic Drug Monitoring*, **1990**, 12, 415-6	3.2	165
46	Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. *Clinical Pharmacology and Therapeutics*, **1990**, 48, 496-502	6.1	55
45	Factors influencing the metabolism of diazepam **1990**, 45, 85-91		26
44	Glucuronidation of amitriptyline in man in vivo. *Basic and Clinical Pharmacology and Toxicology*, **1989**, 65, 37-9		15
43	Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. *Clinical Pharmacology and Therapeutics*, **1989**, 46, 78-81	6.1	153
42	Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 348-55	6.1	229
41	S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 495-9	6.1	117
40	Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 650-6	6.1	28
39	Disposition and Effects of E-10-Hydroxynortriptyline□An Active Metabolite of Nortriptyline **1989**, 620-622		1
38	Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. *Clinical Pharmacology and Therapeutics*, **1988**, 44, 431-5	6.1	135
37	Detection of N-terminally extended substance P but not of substance P in human cerebrospinal fluid: quantitation with HPLC-radioimmunoassay. *Journal of Neurochemistry*, **1988**, 50, 1701-7	6	36
36	Biochemical and clinical effects of amiflamine-determined by the debrisoquine hydroxylation phenotype?. *Nordic Journal of Psychiatry*, **1987**, 41, 141-148		
35	5-Hydroxyindoleacetic acid in cerebrospinal fluid--methodological and clinical aspects. *Life Sciences*, **1987**, 41, 821-4	6.8	12

34	Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. *Clinical Pharmacology and Therapeutics*, **1987**, 42, 10-9	6.1	40
33	Glucuronidation of the enantiomers of E-10-hydroxynortriptyline in human and rat liver microsomes. *Basic and Clinical Pharmacology and Toxicology*, **1987**, 61, 335-41		15
32	Formation of a quaternary N-glucuronide of amitriptyline in human liver microsomes. *Basic and Clinical Pharmacology and Toxicology*, **1987**, 61, 342-6		12
31	Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. *Clinical Pharmacology and Therapeutics*, **1986**, 40, 261-7	6.1	33
30	Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. *Clinical Pharmacology and Therapeutics*, **1986**, 39, 369-71	6.1	84
29	Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. *Journal of Clinical Pharmacology*, **1986**, 26, 459-62	2.9	40
28	Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. *Clinical Pharmacokinetics*, **1986**, 11, 177-98	6.2	210
27	Extremely Rapid Hydroxylation of Debrisoquine. *Therapeutic Drug Monitoring*, **1985**, 7, 478-480	3.2	138
26	Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. *Clinical Pharmacokinetics*, **1985**, 10, 80-90	6.2	147
25	Side-effects of carbamazepine: drug or metabolite?. *Lancet, The*, **1985**, 2, 1010	40	
24	Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. *Clinical Pharmacology and Therapeutics*, **1984**, 35, 815-21	6.1	38
23	Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. *Life Sciences*, **1984**, 35, 1379-83	6.8	16
22	Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. *Clinical Pharmacology and Therapeutics*, **1983**, 33, 58-65	6.1	51
21	Stereospecific 10-hydroxylation of nortriptyline genetic aspects and importance for biochemical and clinical effects **1983**, 217-226		3
20	Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls. *Psychiatry Research*, **1982**, 6, 77-83	9.9	49
19	Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. *Psychiatry Research*, **1981**, 4, 21-9	9.9	252
18	Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. *Clinical Pharmacology and Therapeutics*, **1980**, 27, 83-8	6.1	115
17	Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. *Life Sciences*, **1980**, 27, 1673-7	6.8	99

16	Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. *Life Sciences*, **1979**, 25, 1285-92	6.8	84
15	Techniques for plasma protein binding of demethylchlorimipramine. *Clinical Pharmacology and Therapeutics*, **1979**, 26, 265-71	6.1	32
14	Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. *Pharmacology*, **1979**, 19, 282-7	2.3	20
13	Serotonin in Depressive Illness Studies of CSF 5-HIAA **1979**, 105-115		6
12	Clinical pharmacokinetics of carbamazepine. *Clinical Pharmacokinetics*, **1978**, 3, 128-43	6.2	173
11	DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY - METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS **1976**, 269-276		
10	Pharmacokinetics of indomethacin. *Clinical Pharmacology and Therapeutics*, **1975**, 18, 364-73	6.1	192
9	Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. *Journal of Chromatography A*, **1975**, 103, 135-40	4.5	44
8	Quantitative determination of 4-hydroxy-3-methoxyphenyl glycol and its conjugates in cerebrospinal fluid by mass fragmentography. *Journal of Chromatography A*, **1973**, 87, 147-53	4.5	75
7	Determination of isomeric acid dopamine metabolites in human cerebrospinal fluid by mass fragmentography. *Life Sciences*, **1973**, 13, 859-66	6.8	20
6	Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. *Clinical Pharmacology and Therapeutics*, **1973**, 14, 277-86	6.1	186
5	Quantitative determination of carbamazepine in plasma by mass fragmentography. *Clinical Pharmacology and Therapeutics*, **1973**, 14, 827-32	6.1	47
4	Quantitative determination of 5-hydroxyindole-3-acetic acid in cerebrospinal fluid by gas chromatography-mass spectrometry. *Analytical Chemistry*, **1972**, 44, 1434-8	7.8	103
3	Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. *European Journal of Clinical Pharmacology*, **1972**, 4, 201-205	2.8	53
2	Pharmacokinetics and biological effects of nortriptyline in man. *Acta Pharmacologica Et Toxicologica*, **1971**, 29 Suppl 3, 255-80		19
1	Hydroxylation and subsequent glucuronide conjugation of desmethylimipramine in rat liver microsomes. *Xenobiotica*, **1971**, 1, 205-12	2	25